We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- General Strategies in Biomarker Research
-
1. The proteomic revolution
- Dr. Larry Gold
-
2. Lipid biomarkers: lipidomics of the macrophage and plasma lipidomes
- Prof. Edward A. Dennis
- New Tools for Biomarker Research
-
5. Development of glyco-biomarkers using glycoproteomics technologies
- Dr. Hisashi Narimatsu
-
6. Circulating nucleic acids as biomarkers in cancer patients
- Prof. Klaus Pantel
- Specific Disease Applications
-
7. Biomarkers in breast cancer
- Prof. Joe Duffy
-
8. Bacterial biomarkers
- Dr. Christiane Honisch
-
9. Diabetes biomarkers
- Prof. Naveed Sattar
-
10. Gene networks, brain networks: understanding schizophrenia
- Dr. Daniel Weinberger
-
11. Biomarkers for Huntington's disease - promises and challenges
- Prof. Sarah Tabrizi
-
12. Update on fluid biomarkers for neurodegenerative diseases
- Prof. Henrik Zetterberg
-
13. Biomarkers in osteoarthritis
- Dr. Ali Mobasheri
- Biomarkers in Drug Discovery and Delivery
-
14. Pharmacogenomics: emphasis on clinical drug development
- Dr. Amelia Warner
-
15. Biomarkers in drug development: potential use and challenges
- Dr. Abdel-Bassett Halim
- Biomarkers in development, nutrition, and health
-
18. Ethnic differences in nutrition
- Prof. Jose Ordovas
-
19. Non-invasive prenatal diagnostics
- Prof. Y. M. Dennis Lo
-
20. Epigenetic biomarkers in cancer
- Prof. Bob Brown
- Archived Lectures *These may not cover the latest advances in the field
-
21. Biomarkers for Alzheimer's disease
- Prof. Henrik Zetterberg
Printable Handouts
Navigable Slide Index
- Introduction
- Aim and scope
- Overview of presentation
- Background and context
- Osteoarthritis (OA) (1)
- Osteoarthritis (OA) (2)
- Osteoarthritis (OA) (3)
- Risk factors for OA
- Obesity and OA
- General features of OA
- Loss of homeostasis leads to OA
- The cytokine balance is perturbed in OA
- Repetitive excess mechanical loading
- Synovial, chondral and subchondral changes
- Biomarker: definition
- Rationale for development of OA biomarkers
- The gold standard (radiography) is inadequate
- A better "gold standard"
- Limitations of radiography
- Rationale for identifying early OA biomarkers
- Classification of OA biomarkers: BIPEDs
- Osteoarthritis biomarkers network classification
- OA biomarkers working group
- Classification of OA biomarkers
- Relevance of biomarkers for clinicians & patients
- Relevance to pharmaceutical product pipeline
- The drug pipeline
- Challenges facing the drug pipeline
- The OA drug pipeline
- Surrogate OA biomarkers
- Biochemical marker toolbox in drug discovery
- The biomarker pipeline
- Major classes of OA biomarkers
- Soluble OA biomarkers
- BIPED biomarkers classification
- Classifying biomarkers according to tissue of origin
- Not all biomarkers indicate cartilage catabolism
- The matrisome
- Biomarkers origin: synovial tissues and cells
- Proteomic strategies to identify OA biomarkers
- Differences between OA and RA
- Identification of novel serum OA biomarkers
- Complement proteins as OA biomarkers
- Complement components expression in OA
- Barriers to biomarkers achieving their full potential
- Challenges to OA biomarker discovery
- Performance and measurement of markers
- Summary
- Conclusions (1)
- Conclusions (2)
- Current progress and existing bottlenecks
- Future priorities
- Biomarker combinations
- Biomarkers of joint overuse and injury
- Take home message
- Acknowledgements
Topics Covered
- Diagnosis of osteoarthritis
- Issues with radiographic diagnosis
- Lack of analytical tools and reagents for diagnosis
- Limitations of current biomarkers
- Future opportunities for the pharmaceutical industry
Talk Citation
Mobasheri, A. (2013, January 24). Biomarkers in osteoarthritis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 7, 2024, from https://doi.org/10.69645/XIDY6204.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Ali Mobasheri has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Biomarkers in osteoarthritis.
Ali Mobasheri.
0:06
The aim of this presentation
is to provide an overview
of current research on
osteoarthritis biomarkers.
Highlight the lack of
analytical tools and
reagents in our currently
available toolbox.
Discuss the limitations of
currently available biomarkers.
We will also explore future
opportunities and identify
key areas that are relevant to
the pharmaceutical
product pipeline.
0:30
This presentation will
summarise the definition
of osteoarthritis and the
biomarkers of osteoarthritis
and highlights the need for
a better "gold standard"
because radiography is
currently inadequate.
The presentation
will also discuss
recent developments in
biomarker definition
and classification and
introduce the concepts
of "wet" and "dry" biomarkers.
I will also discuss
post-genomic approaches
for the identification of new
osteoarthritis biomarkers
aimed at early pre-radiographic
identification of disease.
I will discuss the advent of
"combination biomarkers".
1:07
Before discussing biomarkers
of osteoarthritis,
I will need to provide some
background information
about osteoarthritis.
1:16
Osteoarthritis is the most
common form of arthritis
in humans and companion animals,
and it is a major cause
of pain, inflammation
and loss of mobility.
1:28
Osteoarthritis is
characterised by
progressive deterioration
and loss of articular cartilage.
It affects load-bearing
synovial joints
and is associated with ageing
and excessive or
abnormal joint loading.